Qtis.ai Launches AI-Native Clinical Research Division, Enters Fast-Growing $7.4 Billion CTMS Market
New platform aims to modernize decades-old clinical research infrastructure with purpose-built AI architecture
Qtis.ai, an applied artificial intelligence company focused on healthcare, medical research, and aesthetics, today announced the launch of its Clinical Research Division and the commercial deployment of its AI-native Clinical Trial Management System (CTMS), a next-generation platform designed specifically for the AI era.
The company also announced its first CTMS customer, Cardiac Dimensions, Inc. (CDI), a privately held medical device company headquartered in Kirkland, Washington. CDI develops minimally invasive catheter-based technologies for the treatment of heart failure and functional mitral regurgitation (FMR) and operates clinical programs globally.
The announcement marks Qtis’ entry into one of healthcare’s fastest-growing software categories. According to Grand View Research, the global Clinical Trial Management System market was valued at approximately $2.4 billion in 2025 and is projected to reach $7.4 billion by 2033, driven by increasing trial complexity, regulatory requirements, and growing demand for digital clinical infrastructure.
